Home LiteratureArticle Details
PMID: 3283097 Published · ppublish English Clinical Trial Comparative Study Controlled Clinical Trial Journal Article Randomized Controlled Trial

Enoxacin in the treatment of sexually transmitted diseases.

The Journal of antimicrobial chemotherapy ·Vol. 21 Suppl B ·1988-02-00 ·Pages 119-24

Siboulet A, Bohbot JM, Catalan F

Abstract

Enoxacin was evaluated in two double-blind comparative trials in a total of 200 male and female patients with urethral and/or endocervical gonorrhoea. Single 400-mg doses were effective in eradicating Neisseria gonorrhoeae (including penicillinase-producing strains) from patients. Enoxacin was as effective as the parenteral drugs approved for treatment. Adverse events occurred in 3% of patients. Enoxacin has been shown to be an effective well tolerated and convenient treatment for gonorrhoea.

MeSH Terms
Adult Anti-Infective Agents/administration & dosage,therapeutic use Clinical Trials as Topic Double-Blind Method Drug Administration Schedule Enoxacin Female Gonorrhea/drug therapy Humans Male Middle Aged Naphthyridines/administration & dosage,therapeutic use Random Allocation Sexually Transmitted Diseases/drug therapy Urethritis/drug therapy Uterine Cervicitis/drug therapy
Chemicals
Anti-Infective Agents Naphthyridines Enoxacin
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Siboulet A
Institut Alfred Fournier, Paris, France.
Bohbot J M
Catalan F
Article Info
Journal
The Journal of antimicrobial chemotherapy
Abbr.
J Antimicrob Chemother
ISSN
0305-7453
Published
1988-02-00
Pages
119-24
Language
English
Region
England
NLM ID
7513617
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]